Inicio › Carcinoma de células escamosas de cabeza y cuello › Ohio

Ensayos clínicos de Carcinoma de células escamosas de cabeza y cuello en Ohio

46 estudios sobre Carcinoma de células escamosas de cabeza y cuello buscan participantes en Ohio.

Ciudades en Ohio

Texto oficial del estudio (inglés)

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 10, Columbus

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07085091

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Miami Valley Hospital South, Centerville
Miami Valley Hospital, Dayton
Miami Valley Hospital North, Dayton
y 3 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06589804

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Site 06, Maumee

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07814248

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

University of Cincinnati, Cincinnati
Ohio State University, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07276399

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Cleveland Clinic, Cleveland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06385080

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
University of Cincinnati Cancer Center-West Chester, West Chester

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06980038

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Miami Valley Hospital South, Centerville
Premier Blood and Cancer Center, Dayton
Miami Valley Hospital North, Dayton
y 2 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05136196

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

University of Cincinnati, Cincinnati

ReclutandoFase 3

Edades de 60 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04892173

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Miami Valley Hospital South, Centerville
Cleveland Clinic Foundation, Cleveland
Premier Blood and Cancer Center, Dayton
y 3 más

ReclutandoFase 2

Edades de 18 a 79 · Todos los sexos · Actualizado el 22 sept 2026 · NCT04671667

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

UH Cleveland Medical Center, Cleveland

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07109726

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Cleveland Clinic, Cleveland
Toledo Clinic Cancer Center, Toledo

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT05059444

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

UH Seidman Cancer Center at UH Avon Health Center, Avon
Indu and Raj Soin Medical Center, Beavercreek
Saint Elizabeth Boardman Hospital, Boardman
y 22 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT02734537

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Cleveland Clinic, Cleveland
Ohio State University, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06657222

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site, Columbus

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 sept 2026 · NCT06535607

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06465069

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

University of Cincinnati, Cincinnati
Cleveland Clinic, Cleveland
Ohio State University, Columbus

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06163534

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ohio State University, Columbus

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06769698

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Normunity Investigational Site, Maumee

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT07182149

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Summa Health System - Akron Campus, Akron
Aultman Health Foundation, Canton
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
y 2 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06532279

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
ProMedica Flower Hospital, Sylvania
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT07441681

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Cleveland Clinic Foundation, Cleveland
Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT04333537

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The Ohio State University, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 ago 2026 · NCT05985655

SMP-3124LP in Adults With Advanced Solid Tumors

Ohio State University, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT06526819

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT06627270

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #10, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT05176483

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Cleveland Clinic, Cleveland
Ohio State University, Columbus
Taylor Cancer Research Center, Maumee

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jul 2026 · NCT03526835

Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer

Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 jul 2026 · NCT04754321

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 jul 2026 · NCT05208762

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Site#0154, Canton
Site#0117, Cincinnati
Site #0151, Cleveland
y 1 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jul 2026 · NCT06788990

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

UH Cleveland Medical Center, Cleveland
Stefanie Spielman Comprehensive Breast Center, Columbus

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 7 jul 2026 · NCT05768139

Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma

University of Cincinnati Medical Center, Cincinnati

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 jul 2026 · NCT07213934

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

GSK Investigational Site, Canton

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 may 2026 · NCT06256588

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

University of Cincinnati Medical Center, Cincinnati

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 may 2026 · NCT07497607

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Aultman Health Foundation, Canton

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 11 may 2026 · NCT06992427

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

The Cleveland Clinic Foundation, Cleveland

ReclutandoFase 2/3

Edades de 18 a 100 · Todos los sexos · Actualizado el 23 abr 2026 · NCT05893888

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06064877

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 abr 2026 · NCT05785741

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Ohio State University Comprehensive Cancer Center, Columbus

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT06323460

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Cleveland Clinic, Cleveland
Taylor Cancer Research Center, Maumee

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 feb 2026 · NCT07030257

Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

Ohio State University Medical Center, Columbus

Reclutando

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 feb 2026 · NCT01473784

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.